BioNTech SE

Company Profile

BioNTech SE had its IPO on 2019-10-10 under the ticker symbol BNTX.

The company operates in the Healthcare sector and Biotechnology industry. BioNTech SE has a staff strength of 5,100 employees.

Stock update

Shares of BioNTech SE opened at $116.26 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $113.22 - $117.42, and closed at $115.63.

This is a -1.97% slip from the previous day's closing price.

A total volume of 964,424 shares were traded at the close of the day’s session.

In the last one week, shares of BioNTech SE have slipped by -5.03%.

BioNTech SE's Key Ratios

BioNTech SE has a market cap of $26.20 billion, indicating a price to book ratio of 2.3324 and a price to sales ratio of 2.3797.

In the last 12-months BioNTech SE’s revenue was $12.21 billion with a gross profit of $16.07 billion and an EBITDA of $8.13 billion. The EBITDA ratio measures BioNTech SE's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, BioNTech SE’s operating margin was 65.98% while its return on assets stood at 23.77% with a return of equity of 34.49%.

In Q1, BioNTech SE’s quarterly earnings growth was a negative -85.6% while revenue growth was a negative 80%.

BioNTech SE’s PE and PEG Ratio

Forward PE

9.8912

Trailing PE

3.8502

PEG

0.0449

Its diluted EPS in the last 12-months stands at $28.24 per share while it has a forward price to earnings multiple of 9.8912 and a PEG multiple of 0.0449. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioNTech SE’s profitability.

BioNTech SE stock is trading at a EV to sales ratio of 1.6853 and a EV to EBITDA ratio of 2.1381. Its price to sales ratio in the trailing 12-months stood at 2.3797.

BioNTech SE stock pays annual dividends of $0 per share, indicating a yield of 1.33% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$22.08 billion

Total Liabilities

$1.55 billion

Operating Cash Flow

$0

Capital Expenditure

$54.80 million

Dividend Payout Ratio

0%

BioNTech SE ended 2024 with $22.08 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $22.08 billion while shareholder equity stood at $20.27 billion.

BioNTech SE ended 2024 with $0 in deferred long-term liabilities, $1.55 billion in other current liabilities, 248600000.00 in common stock, $19.34 billion in retained earnings and $0 in goodwill. Its cash balance stood at $12.14 billion and cash and short-term investments were $12.50 billion. The company’s total short-term debt was $37,400,000 while long-term debt stood at $172.40 million.

BioNTech SE’s total current assets stands at $20.09 billion while long-term investments were $516.80 million and short-term investments were $358.00 million. Its net receivables were $6.99 billion compared to accounts payable of $29.90 million and inventory worth $424.10 million.

In 2024, BioNTech SE's operating cash flow was $0 while its capital expenditure stood at $54.80 million.

Comparatively, BioNTech SE paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$115.63

52-Week High

$188.985

52-Week Low

$100.08

Analyst Target Price

$176.75

BioNTech SE stock is currently trading at $115.63 per share. It touched a 52-week high of $188.985 and a 52-week low of $188.985. Analysts tracking the stock have a 12-month average target price of $176.75.

Its 50-day moving average was $111.39 and 200-day moving average was $127.05 The short ratio stood at 2.52 indicating a short percent outstanding of 0%.

Around 6511.2% of the company’s stock are held by insiders while 1818.2% are held by institutions.